BIOMAT Database Logo BIOMAT Database Logo

Inhibition of lipopolysaccharide activation of 7OZ/3 cells by anti-lipopolysaccharide antibodies. 1988

T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Department of Pathology, University of California, San Diego 92161.

We have investigated the ability of mAb against LPS to inhibit LPS-induced activation of 7OZ/3 pre-B cells. The fine specificity and relative affinity of these mAb for lipid A and LPS were also determined. We found that antibodies inhibited only the activity of glycolipids which they bound with relatively high affinity. However, two high affinity antibodies binding to non-lipid A epitopes did not block cellular activation. Some, but not all, relatively high affinity antibodies binding to the lipid A region of the LPS molecule inhibited biologic activity. The inhibitory antibodies bound to at least two distinct epitopes within the lipid A region. These data suggest that LPS interacts with 7OZ/3 cells in a highly specific fashion.

UI MeSH Term Description Entries
D008050 Lipid A Lipid A is the biologically active component of lipopolysaccharides. It shows strong endotoxic activity and exhibits immunogenic properties.
D008070 Lipopolysaccharides Lipid-containing polysaccharides which are endotoxins and important group-specific antigens. They are often derived from the cell wall of gram-negative bacteria and induce immunoglobulin secretion. The lipopolysaccharide molecule consists of three parts: LIPID A, core polysaccharide, and O-specific chains (O ANTIGENS). When derived from Escherichia coli, lipopolysaccharides serve as polyclonal B-cell mitogens commonly used in laboratory immunology. (From Dorland, 28th ed) Lipopolysaccharide,Lipoglycans
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000907 Antibodies, Bacterial Immunoglobulins produced in a response to BACTERIAL ANTIGENS. Bacterial Antibodies
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000915 Antibody Affinity A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes. Affinity, Antibody,Antibody Avidity,Avidity, Antibody,Affinities, Antibody,Antibody Affinities,Antibody Avidities,Avidities, Antibody
D000918 Antibody Specificity The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site. Antibody Specificities,Specificities, Antibody,Specificity, Antibody

Related Publications

T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Inhibition of lipopolysaccharide-induced activation of immature B cells by anti-mu and anti-delta antibodies and its modulation by interleukin-4.
July 1992, International immunology,
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Inhibition of lipopolysaccharide-induced microglial activation by preexposure to neurotrophin-3.
September 2005, Journal of neuroscience research,
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Inhibition of lipopolysaccharide activation of Kupffer cells by transition metals.
August 2008, The Journal of surgical research,
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
[Alternative complement pathway activation by anti-band 3 antibodies].
November 1987, Schweizerische medizinische Wochenschrift,
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Activation of human B cells and inhibition of their terminal differentiation by monoclonal anti-mu antibodies.
July 1985, Journal of immunology (Baltimore, Md. : 1950),
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Inhibition of lipopolysaccharide mitogenicity with characterized anti-lipid A monoclonal antibodies.
November 1985, Immunology,
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Anti-lipopolysaccharide core antibodies.
January 1994, Progress in clinical and biological research,
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Anti-lipopolysaccharide antibodies: update.
October 1984, Lancet (London, England),
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Opsonisation of gram-negative bacteria by anti-lipopolysaccharide antibodies.
November 1985, Lancet (London, England),
T N Kirkland, and E J Ziegler, and P Tobias, and D C Ward, and S M Michalek, and J R McGhee, and I Macher, and K Urayama, and B J Appelmelk
Selective inhibition of transformed cells in culture by anti-thymidine antibodies.
November 1971, Nature: New biology,
Copied contents to your clipboard!